Testing QA108 for intermediate AMD
Part of Eyes & vision clinical trials.
This trial tests an investigational medicine (QA108) for people with intermediate age-related macular degeneration (AMD). It aims to slow or prevent progression of the disease by treating the deposits (drusen) in the center of the retina.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 45 and 85 years old.
- The study eye has medium-stage age-related macular degeneration (AMD) with at least one large drusen (a yellowish deposit under the retina).
- Your vision in that eye is between 20/20 and 20/200 on an eye chart.
- You cannot have other serious eye conditions (like glaucoma, diabetic retinopathy, or a detached retina) in the study eye.
- You have not had certain eye surgeries or laser treatments in the study eye in the past 3 months.
- You agree to avoid pregnancy and follow study medication rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a traditional Chinese medicine pill, Sanhuang Jingshiming, for people with a specific type of wet age-related macular degeneration (nAMD) that is active. It aims to see if the pill can help improve vision and is safe compared to standard care.
This study tests a new medicine called IBI302 for wet age-related macular degeneration (AMD). It aims to slow vision loss by targeting both blood vessel growth and inflammation. You might qualify if you have active wet AMD and have not had certain injections recently.
This study looks at people with intermediate age-related macular degeneration (AMD), a common eye condition that can affect central vision. The researchers want to better understand how AMD changes over time by using different types of eye scans. This may help find ways to monitor the condition and guide future treatments.
This study uses artificial intelligence to track changes in the eyes of people with early or intermediate age-related macular degeneration (AMD). It aims to better understand how the disease progresses and may help doctors personalize care.
This study tests a new laser treatment (MacuTherm) for intermediate age-related macular degeneration (iAMD), an eye condition that affects central vision. The study aims to see if this treatment can slow or prevent progression to more advanced stages of the disease.
This trial uses artificial intelligence to track changes in the eyes of people with advanced age-related macular degeneration (AMD) that has caused a specific type of damage (atrophy) in the retina. The goal is to see if AI can help detect when the disease gets worse, so doctors can personalize monitoring for each patient.
Hear when a new Intermediate Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.